You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm also reported that both preliminary 2016 revenues and preliminary Q4 revenues would be down 3 percent.
The revenue increase was driven by growth in sales of both instrument systems and consumables.
A big bump in service revenues made up for a decline in product revenues. The company also trimmed its operating expenses and narrowed its net loss.
Interpace shares were up 17 percent in early morning trading on the Nasdaq, as it reported a profitable quarter compared to a loss in the prior-year quarter.
The firm’s biopharma revenues increased 11 percent, while clinical service revenues grew 20 percent, and discovery service revenue increased 12 percent.
The company signed a US partnership agreement for its portfolio of early cancer detection tests with lab testing services provider Any Lab Test Now.
Despite strong molecular diagnostics product sales growth, the firm's overall diagnostics business was down almost 3 percent year over year.
The firm, which is battling the fallout from a negative news report, missed the consensus Wall Street estimates on the top and bottom lines.
Natera said that the new product would further establish the company as a one-stop shop in the reproductive health market from pre-pregnancy through birth.
The company attributed the revenue decline to the conclusion of agreements with licensing partners for the sale of its products.